OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs
“In the second quarter, our work to leverage our scientific and technological expertise against the COVID-19 pandemic has already generated meaningful revenue. Our sample collection devices are being used for the collection, both in at-home and professional settings, and transport of samples for COVID-19 molecular testing. We are also developing a COVID-19 rapid antigen in-home self-test and an ELISA-based oral fluid COVID-19 antibody test, both of which we now expect to launch in the fourth quarter,” said
“We further strengthened our balance sheet in June with the completion of an equity offering that included investments from top institutional healthcare investors, bringing us to
Second Quarter Financial Highlights
- Net revenues for the second quarter of 2020 were $29.3 million, a 25% decrease from the second quarter of 2019. Net product and services revenues were $28.3 million, a 24% decrease from the second quarter of 2019. Excluding cryosurgical revenues, the line of business the Company divested in August 2019, and revenues from the Diversigen subsidiary, which the Company acquired in November 2019, net revenues and product and services revenues declined 21% and 20%, respectively, from the second quarter of 2019.
- Other revenue highlights:
- Total product and service revenues for the Company’s molecular business unit were
$18.1million during the second quarter of 2020, an increase of 4% from the second quarter of 2019. This increase included $8.5 millionin sales of oral fluid collection devices for COVID-19 molecular testing.
- International sales of the Company’s OraQuick® HIV products decreased 28% compared to the second quarter of 2019. This decrease was due to delays of shipments which moved from the end of the second quarter into the early third quarter.
- Total laboratory service revenues in the second quarter of 2020 were $2.2 million compared to $1.2 million in the second quarter of 2019. Laboratory services in 2020 include the revenues generated by both of the Company’s laboratory service subsidiaries, which are now operating under the Diversigen brand.
- Net loss for the second quarter of 2020 was $10.5 million, or $0.16 per share on a fully-diluted basis, compared to net income of $4.4 million, or $0.07 per share on a fully-diluted basis, for the second quarter of 2019. Net loss for the second quarter of 2020 included a $660,000 non-cash pre-tax benefit associated with the change in fair value of acquisition-related contingent consideration and
$195,000of acquisition-related transaction costs. Net income in the second quarter of 2019 included a $249,000 non-cash pre-tax charge associated with the change in the fair value of acquisition-related contingent consideration. The impact of these items were negligible to earnings per share in both periods.
- Cash and investments totaled $265.8 million at June 30, 2020, including
$95 millionin proceeds from an equity offering completed in June.
COVID-19 Program Update
- Use of existing oral fluid collection devices in molecular COVID-19 testing generated
$8.5Min revenue in the second quarter. In the second quarter, devices from OraSure’s DNA Genoteksubsidiary, including the ORAcollect RNA collection kit, OMNIgene ORAL saliva collection device, and Oragene®•Dx device, were included in U.S. Food and Drug Administration (FDA) Emergency Use Authorizations (EUAs) granted to four customers. The EUAs granted to Clinical Reference Laboratory(CRL), Biocerna, P23 Labsand Phosphorous enable the Company’s devices to be used for supervised and unsupervised COVID-19 sample collection with their EUA assays for the detection of SARS-CoV-2. OraSure’s devices are also currently being used as part of several back-to-school and back-to-work programs across the country. The Company expects one or more of its products to be included in several additional EUAs to be granted in the near future.
- OraQuick Coronavirus Rapid Antigen Self-Test on track for EUA submission and subsequent launch in the fourth quarter.
OraSureis developing a rapid antigen self-test, designed to produce a result for active COVID-19 infection within minutes, with no instrumentation needed to interpret the results and no need to transport samples to a lab for processing, enabling the detection of COVID-19 infection anytime, anywhere. The development of the test is supported by $710,310of funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS). The test is currently in human clinical testing. Although originally intended for use with oral fluid, this test has been modified to employ an easily and comfortably self-collected lower nostril sample in order to achieve the best possible accuracy. The Company fully expects to meet or exceed applicable FDA performance requirements, with EUA filing and subsequent commercial launch in the fourth quarter, pending regulatory approvals. To date, there are no COVID-19 tests for active infection which provide a result at the point of collection with no need for a diagnostic instrument to interpret the result.
- OraSure SARS-CoV-2 Antibody test anticipated to launch in the fourth quarter. The Company is also developing an Enzyme-Linked Immunosorbent Assay (ELISA) using oral fluid to detect human anti-SARS-CoV-2 antibodies that would enable specimen collection in any location, promoting social distancing. The test would utilize the Company’s existing OraSure® oral fluid specimen collection device. To date, there are no commercially available anti-SARS-CoV-2 antibody tests using oral fluid samples with automated assays. In June,
OraSurereceived $629,217 in funding from BARDA to support the development of this test. OraSurehas completed the final product design and this test is currently in human clinical testing. The Company fully expects to meet or exceed applicable FDA performance requirements for this product, file for EUA, and launch in the fourth quarter, pending regulatory approvals.
The pan-SARS-coronavirus antigen rapid in-home self-test project has been funded in whole or in part with Federal funds from the
Department of Health and Human Services, Office of the AssistantSecretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00061. The SARS-CoV-2 antibody test has been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the AssistantSecretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00122.
Additional Second Quarter Business Highlights
- Continued progress in executing on innovation-driven growth strategy with purchase of
UrSure, Inc., strengthening OraSure’s global leadership in the HIV testing field. In May, the Company announced that it had entered into a definitive agreement to acquire privately-owned UrSure, Inc., a company developing and commercializing products that measure adherence to HIV medications that prevent (Pre-Exposure Prophylaxis or PrEP) and treat HIV. This cash transaction, which approximated $3.1 million, closed in July and supports OraSure’s strategy of expanding its core offerings to include additional diagnostic products, particularly point-of-care tests that complement its current infectious disease portfolio and pipeline. OraSurewill be able to offer a full HIV portfolio that covers the spectrum from screening to treatment adherence, two pillars of the federal government’s “Ending the HIV Epidemic: A Plan for America” initiative.
- Continued expansion of sample collection products to meet the needs of research and academic institutions. In June, the Company, through its
DNA Genoteksubsidiary, introduced the OMNImet™·GUT (ME-200) device for metabolomics, the first and only commercially available research use only device for in-home, self-collection of fecal samples for metabolomics. This product augments the Company’s portfolio of multiomic sample collection products.
Financial Results for the Three Months Ended
Net product and service revenues for the second quarter of 2020 decreased 24% from the comparable period of 2019, primarily as a result of lower sales of the Company’s genomics products due to the timing of orders placed by one of the Company’s largest genomics customers and due to the impact of the COVID-19 pandemic. The decline is also a result of lower sales of the Company’s OraQuick® HIV, OraQuick® HCV, and risk assessment products due to reduced research and testing as a result of the COVID-19 pandemic, and the absence of cryosurgical systems revenues, partially offset by the inclusion of product sales related to COVID-19 and higher laboratory services revenues.
Royalty income from a litigation settlement associated with a molecular collection device was $727,000 and $1.1 million for the second quarters of 2020 and 2019, respectively. Other revenues were $195,000 and $445,000 for the second quarter of 2020 and 2019 respectively.
Gross profit percentage was 59% and 64% for the three months ended June 30, 2020 and 2019, respectively. Gross profit percentage in the second quarter of 2020 was negatively affected by lower labor utilization as the Company increased its manufacturing headcount with full-time and temporary employees to prepare for expected production expansion later in the year, a less favorable overall product mix as a result of higher sales of lower gross profit products and services, and the decline in other revenues which contribute 100% to the Company’s gross profit percentage.
For the three months ended June 30, 2020, operating expenses were $26.7 million, an increase of $6.9 million from the $19.7 million reported for the three months ended June 30, 2019. This increase was due primarily to increased spending associated with COVID-19 product development, increased staffing costs, higher bad debt associated with uncollectible customer accounts, higher legal fees, and the inclusion of Diversigen operating expenses, all partially offset by lower spending on market studies, tradeshows and travel.
The Company generated an operating loss of $9.4 million in the second quarter of 2020 compared to operating income of $5.3 million in the second quarter of 2019.
During the second quarter of 2020 and 2019, the Company recorded income tax expense of $1.3 million and
Financial Results for the Six Months Ended
Net product and service revenues for the six months ended
For the six months ended
Gross profit percentage was 55% and 63% for the six months ended
For the six months ended
The Company generated an operating loss of
During the first half of 2020, the Company recorded income tax expense of
For the six months ended
Full-Year 2020 Guidance
As announced last quarter, the Company has withdrawn its full-year 2020 financial guidance due to the unpredictable impact – both positive and negative – of the ongoing COVID-19 global pandemic on its results of operations, and the Company will not be reinstating financial guidance at this time.
Consolidated Financial Data
(in thousands, except per-share data)
|Three Months Ended||Six Months Ended|
|Results of Operations|
|Cost of products and services sold||11,995||13,808||27,460||25,850|
|Research and development||6,924||4,535||12,568||8,906|
|Sales and marketing||10,121||7,687||17,490||14,982|
|General and administrative||10,280||7,262||20,334||16,192|
|Change in fair value of acquisition-related contingent consideration||(660||)||249||450||1,544|
|Total operating expenses||26,665||19,733||50,842||41,624|
|Operating income (loss)||(9,401||)||5,285||(17,447||)||1,474|
|Income (loss) before income taxes||(9,185||)||5,809||(15,801||)||2,522|
|Income tax expense||1,309||1,411||2,021||1,382|
|Net income (loss)||$||(10,494||)||$||4,398||$||(17,822||)||$||1,140|
|Income (loss) per share:|
|Weighted average shares:|
|Three Months Ended
|Dollars||Percentage of Total Net
|Infectious disease testing||$||8,737||$||13,348||(35||)||%||30||%||34||%|
|Risk assessment testing||1,533||3,097||(51||)||5||8|
|Molecular collection systems||18,067||17,304||4||63||45|
|Net product and service revenues||28,337||37,267||(24||)||98||96|
|Six Months Ended
|Dollars||Percentage of Total Net
|Infectious disease testing||$||23,400||$||25,686||(9||)||%||38||%||37||%|
|Risk assessment testing||4,533||5,934||(24||)||7||9|
|Molecular collection systems||31,290||27,886||12||52||40|
|Net product and service revenues||59,223||65,599||(10||)||97||95|
|Three Months Ended||Six Months Ended|
|Net HIV revenues||7,080||9,882||(28||)||18,246||18,188||—|
|Net HCV revenues||1,398||3,085||(55||)||3,989||6,370||(37||)|
|Net product revenues||$||8,478||$||12,967||(35||)||%||$||22,235||$||24,558||(9||)||%|
|Three Months Ended||Six Months Ended|
|Molecular Collection Systems Revenues|
|Other product revenues||49||108||(55||)||78||317||(75||)|
|Net molecular product and service revenues||18,067||17,304||4||31,290||27,886||12|
|Net molecular product and service revenues||$||18,832||$||18,454||2||%||$||32,636||$||30,343||8||%|
|Condensed Consolidated Balance Sheets (Unaudited)
|Cash and cash equivalents||$||173,874||$||75,715|
|Accounts receivable, net||25,918||36,948|
|Other current assets||7,799||8,109|
|Property, plant and equipment, net||33,763||30,339|
|Intangible assets, net||15,221||14,674|
|Other non-current assets||9,413||10,111|
|Liabilities and Stockholders’ Equity|
|Contingent consideration obligation||560||3,500|
|Other current liabilities||16,054||15,933|
|Other non-current liabilities||8,482||9,437|
|Total liabilities and stockholders’ equity||$||420,827||$||349,295|
|Additional Financial Data (Unaudited)||Six Months Ended|
|Depreciation and amortization||$||4,600||$||3,610|
|Cash provided by (used in) operating activities||$||(2,184||)||$||4,661|
The Company will host a conference call and audio webcast for analysts and investors to discuss the Company’s 2020 second quarter results and certain business developments, beginning today at 5:00 p.m. Eastern Time (
In order to listen to the conference call, please dial 844-831-3030 (Domestic) or 315-625-6887 (International) and reference Conference ID #3276612 or go to OraSure Technologies’ web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call will be archived on OraSure Technologies’ web site shortly after the call has ended and will be available for seven days. A replay of the call can also be accessed until midnight, August 12, 2020, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering the Conference ID #3276612.
Given the circumstances globally, it is recommended to dial-in at most 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on OraSure’s Investor Relations page.
This press release contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to successfully manage and integrate acquisitions of other companies in a manner that complements or leverages our existing business, or otherwise expands or enhances our portfolio of products and our end-to-end service offerings, and the diversion of management’s attention from our ongoing business and regular business responsibilities to effect such integration; the expected economic benefits of acquisitions (and increased returns for our stockholders), including that the anticipated synergies, revenue enhancement strategies and other benefits from the acquisitions may not be fully realized or may take longer to realize than expected and our actual integration costs may exceed our estimates; impact of increased or different risks arising from the acquisition of companies located in foreign countries; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on our business and our ability to successfully develop new products, validate the expanded use of existing collector products and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
|Investor contact:||Media contact:|
|VP Corporate Communications|
Source: OraSure Technologies, Inc.